Capecitabine in the Treatment of Advanced Gastric Cancer

Jae-Lyun Lee; Yoon-Koo Kang


Future Oncol. 2008;4(2):179-198. 

In This Article

Future Perspective

Oral fluoropyrimidines such as capecitabine and, probably, S-1 will replace infusional 5-FU in the adjuvant setting as well as in the palliative setting for the treatment of AGC. The combination of molecular targeting agents with oral fluoropyrimidine combination chemotherapy may have a significant impact in AGC, since some of these tumors show upregulation of VEGF, EGFR and Her2/neu, and bevacizumab, cetuximab and trastuzumab have shown successful results in patients with colorectal cancer and breast cancer. The combination of trastuzumab with capecitabine and cisplatin is being actively investigated in an international, multicenter, Phase III study (Study of Herceptin (Trastuzumab) in Combination with Chemotherapy Compared with Chemotherapy Alone in Patients with HER2-positive Advanced Gastric Cancer [TOGA] study), and the combination of bevacizumab or cetuximab with capecitabine and cisplatin will be tested in future Phase III trials. In addition, a Phase III study assessing the role of panitumumab when combined with EOX in gastric cancer is planned in the UK.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.